Table 3

Treatment-related adverse events

Arm A pBCAR3
n=3
Arm B pIRS2
n=3
Arm C Both
n=9
Total
n=15
CategoryAdverse eventG1G2G3G1G2G3G1G2G3G1G2G3
GastrointestinalConstipation11
Diarrhea123
Mucositis oral11
Nausea213
General and
administration site
Chills1113152
Edema limbs11
Fatigue2125192
Fever1113
Influenza like symptoms1111
Injection site reaction33915
Pain22
Immune systemAutoimmune disorder213
InvestigationsLymphocyte count decreased11
Metabolism/nutritionAnorexia11
Musculoskeletal/
connective tissue
Arthralgia134
Myalgia246
Nervous systemDizziness123
Headache11451
PsychiatricAgitation11
Respiratory/thoracic/
mediastinal
Cough11
Sore throat11
Skin/subcutaneous tissueDry skin11
Skin induration314558
Skin ulceration1111
VascularFlushing11
Hot flashes11
Participant highest grade*Any33915
  • *There were no grade 3–5 treatment-related adverse events.

  • pBCAR3, phosphopeptide from breast cancer antiestrogen resistance 3; pIRS2, phosphopeptide from insulin receptor substrate 2.